Positive associations between circulating FGF-23 levels and hepatic steatosis, adiposity, and circulating hyperlipidaemia have been described42,43 and therefore following weight loss intervention withdrawal, a differential impact on circulating FGF-23 levels could have a metabolic impact. This evidence concerns the gene FGF23 and hyperlipidemia.